Spero Therapeutics to Present Data at IDWeek 2021

CAMBRIDGE, Mass., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc.(Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced 23 data presentations at the Infectious Disease Society of America (IDSA) IDWeekTM 2021, taking place virtually from September 29 October 3, 2021.